Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

Phase 4

Completed

• Conditions: Neoplastic CNS Lesions
• Interventions: Drug: Gadovist® (Gadobutrol, BAY86-4875); Drug: Dotarem

• Registration Number: NCT00764387
• Lead Sponsor: Bayer

Brief Summary

Study to compare of two contrast agents in imaging brain lesions.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-03
• Study First Submitted: 2008-07-03
• Study First Submitted QC: 2008-10-01
• Study First Posted: 2008-10-02
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-04
• Last Update Posted: 2014-12-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 166

Inclusion Criteria

• Known neoplastic CNS lesions

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 1	Gadovist® (Gadobutrol, BAY86-4875)	-
Arm 2	Dotarem	-

Primary Outcome Measures

Name	Time	Method
The primary analysis will be the comparison of the enhancements characteristics of Gadobutrol and Gd-TOTA on a lesion per lesion basis.	October 2007 to November 2008